Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR) a prospective, multicentre, single-arm study

Background Surgery remains the only recommended intervention for patients with native aortic regurgitation. A transcatheter therapy to treat patients at high risk for mortality and complications with surgical aortic valve replacement represents an unmet need. Commercial transcatheter heart valves in pure aortic regurgitation are hampered by unacceptable rates of embolisation and paravalvular regurgitation. The Trilogy transcatheter heart valve (JenaValve Technology, Irvine, CA, USA) provides a treatment option for these patients. We report outcomes with transfemoral transcatheter aortic valve implantation (TAVI) in patients with pure aortic regurgitation using this dedicated transcatheter heart valve.<br /> Methods The ALIGN -AR trial is a prospective, multicentre, single -arm study. We recruited symptomatic patients (aged >= 18 years) with moderate -to -severe or severe aortic regurgitation at high risk for mortality and complications after surgical aortic valve replacement at 20 US sites for treatment with the Trilogy transcatheter heart valve. The 30 -day composite primary safety endpoint was compared for non -inferiority with a prespecified performance goal of 40<middle dot>5%. The primary efficacy endpoint was 1 -year all -cause mortality compared for non -inferiority with a performance goal of 25%. This trial is registered with ClinicalTrials.gov, NCT 04415047, and is ongoing.<br /> Findings Between June 8, 2018, and Aug 29, 2022, we screened 346 patients. We excluded 166 (48%) patients and enrolled 180 (52%) patients with symptomatic aortic regurgitation deemed high risk by the heart team and independent screening committee assessments. The mean age of the study population was 75<middle dot>5 years (SD 10<middle dot>8), and 85 (47%) were female, 95 (53%) were male, and 131 (73%) were White. Technical success was achieved in 171 (95%) patients. At 30 days, four (2%) deaths, two (1%) disabling strokes, and two (1%) non -disabling strokes occurred. Using standard Valve Academic Research Consortium -2 definitions, the primary safety endpoint was achieved, with events occurring in 48 (27% [97<middle dot>5% CI 19<middle dot>2-34<middle dot>0]) patients (p(non-inferiority) <0<middle dot>0001), with new pacemaker implantation in 36 (24%) patients. The primary efficacy endpoint was achieved, with mortality in 14 (7<middle dot>8% [3<middle dot>3-12<middle dot>3]) patients at 1 year (p(non-inferiority) < 0 <middle dot> 0001 ). Interpretation This study shows the safety and effectiveness of treating native aortic regurgitation using a dedicated transcatheter heart valve to treat patients with symptomatic moderate -to -severe or severe aortic regurgitation who are at high risk for mortality or complications after surgical aortic valve replacement. The observed short-term clinical and haemodynamic outcomes are promising as are signs of left ventricular remodelling, but long-term follow-up is necessary.